Arvinas Inc
$ 11.00
3.97%
14 Apr - close price
- Market Cap 679,493,000 USD
- Current Price $ 11.00
- High / Low $ 11.16 / 10.57
- Stock P/E N/A
- Book Value 6.83
- EPS -1.14
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.16 %
- 52 Week High 14.51
- 52 Week Low 5.90
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$14.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-10-28 | 2025-08-06 | 2025-05-01 | 2025-02-11 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 | 2023-05-05 |
| Reported EPS | -1.1 | -0.48 | -0.84 | 1.14 | -0.63 | -0.68 | -0.49 | -0.97 | -2.53 | -1.18 | -1.25 | -1.54 |
| Estimated EPS | -0.4955 | -0.76 | -0.89 | -0.97 | -0.96 | -0.87 | -0.86 | -1.42 | -1.27 | -1.58 | -1.65 | -1.51 |
| Surprise | -0.6045 | 0.28 | 0.05 | 2.11 | 0.33 | 0.19 | 0.37 | 0.45 | -1.26 | 0.4 | 0.4 | -0.03 |
| Surprise Percentage | -121.998% | 36.8421% | 5.618% | 217.5258% | 34.375% | 21.8391% | 43.0233% | 31.6901% | -99.2126% | 25.3165% | 24.2424% | -1.9868% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARVN
2026-04-08 08:46:32
JPMorgan Chase & Co. significantly increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 475.5% in Q3, now holding 214,779 shares valued at $1.83 million. Despite substantial institutional investment, Arvinas reported a weak quarter with an 84% revenue plunge and missed EPS expectations, leading to a "Hold" consensus among analysts with a $13.88 average price target. Insider activity shows both buying from a director and recent selling, reflecting mixed sentiment around the biopharmaceutical company focused on targeted protein degradation.
2026-04-03 19:41:00
This article provides a technical analysis of Arvinas Inc (ARVN), indicating a "Sell" consensus based on various indicators. It details the company's moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels. The analysis highlights that while some individual moving averages show "Buy" signals, the overall technical sentiment points towards a "Sell" for ARVN.
2026-04-02 20:09:40
Arvinas (ARVN) shares jumped 6.9% following positive investor expectations for its pipeline, specifically encouraging data from an early-stage study of ARV-102 for Parkinson's disease. Despite this, the company faces negative earnings estimate revisions for the upcoming quarter, with expected losses and a significant drop in revenue. The stock currently holds a Zacks Rank #3 (Hold), prompting a watchful eye on whether its recent gain can be sustained.
2026-04-02 17:40:17
Arvinas (NASDAQ:ARVN) shares dropped 5.1% after reporting a significant earnings and revenue miss for Q4, with EPS at ($1.10) against an estimated ($0.55) and revenue of $9.5M versus $37.26M consensus. Despite analyst price target increases and several "Buy" ratings, the stock holds a mixed "Hold" consensus due to the substantial revenue decline. Insider selling and institutional ownership percentages are also detailed.
2026-04-02 13:40:17
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism over promising early-phase trial results for ARV-102, a Parkinsons' disease treatment candidate. Despite this positive momentum, the company faces projected quarterly losses and a significant decline in revenue expectations, and its consensus EPS estimates have been lowered. The stock currently holds a Zacks Rank #3 (Hold).
2026-04-02 08:10:39
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism following positive early-phase trial results for ARV-102, a Parkinson's disease treatment candidate. Despite the recent stock increase, the company faces a projected quarterly loss and a significant revenue drop year-over-year, alongside recent downward revisions in EPS estimates. Investors are advised to monitor the stock, which currently holds a Zacks Rank #3 (Hold).
